APA (7th ed.) Citation

LM, S., M, A., U, B. R., MB, B., RW, C., DM, H., . . . LV, F. (2024). Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation. Archives of pathology & laboratory medicine, 148(7), 757. https://doi.org/10.5858/arpa.2023-0536-CP

Chicago Style (17th ed.) Citation

LM, Sholl, et al. "Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation." Archives of Pathology & Laboratory Medicine 148, no. 7 (2024): 757. https://doi.org/10.5858/arpa.2023-0536-CP.

MLA (9th ed.) Citation

LM, Sholl, et al. "Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation." Archives of Pathology & Laboratory Medicine, vol. 148, no. 7, 2024, p. 757, https://doi.org/10.5858/arpa.2023-0536-CP.